Max Robotics — Global Service Robot Directory + US Certification

About

Takayuki Sumiyoshi is a urologic surgeon and researcher whose work focuses on optimizing surgical outcomes in robot-assisted procedures for prostate and kidney cancers. His major contributions center on clarifying how patient-specific factors—such as aging and antiplatelet therapy—affect bleeding complications and recovery after robot-assisted radical prostatectomy (RARP). Notably, his 2024 study on thienopyridine-class antiplatelets (ticlopidine, clopidogrel, prasugrel) provided critical evidence for perioperative management, earning 7 citations. He has also reevaluated the oncological value of extended pelvic lymph node dissection in the RARP era, analyzing data from over 8,000 patients to guide real-world treatment decisions. Beyond prostate cancer, Sumiyoshi has investigated trifecta outcomes—a composite measure of cancer control, renal function, and complication avoidance—in robot-assisted partial nephrectomy for T1b renal tumors. His work on neurovascular bundle preservation for high-risk prostate cancer further demonstrates his commitment to balancing oncologic efficacy with functional preservation. With multiple publications in 2023–2025, Sumiyoshi is establishing himself as a thoughtful voice in minimally invasive urologic oncology, helping to refine surgical techniques and patient selection for better long-term outcomes.